GEN Pharma获得批准, 从2026年4月开始在荷兰的早期帕金森病人中测试SUL-238。 GEN Pharma gets approval to test SUL-238 in early Parkinson’s patients in the Netherlands starting April 2026.

GEN制药公司获得了道德认可,从2026年4月开始,在荷兰未经治疗的Parkinson病人的早期开始对其实验药物SUL-238进行第二阶段试验。 GEN Pharmaceuticals has received ethical approval to begin a Phase II trial for its experimental drug SUL-238 in early, untreated Parkinson’s patients in the Netherlands, starting April 2026. 在格罗宁根进行的SHEPHERD研究将评估SUL-238是否有能力利用脑成像来提高米托氏体功能。 The SHEPHERD Study, conducted in Groningen, will assess SUL-238’s ability to improve mitochondrial function using brain imaging. 该药物旨在增加细胞的能源生产,在早期试验中显示出安全和大脑渗透,目前正在根据荷兰生物技术Sulfateq B.V.的许可证开发。 Mitochondrial机能失调与帕金森的进化有关,帕金森目前缺乏减缓其行进速度的治疗方法。 The drug, designed to boost energy production in cells, showed safety and brain penetration in earlier trials and is being developed under license from Dutch biotech Sulfateq B.V. Mitochondrial dysfunction is linked to Parkinson’s progression, which currently lacks treatments to slow its course.